# Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer

> **NCT05043532** · NA · UNKNOWN · sponsor: **Orlando Health, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Neoplasms
- Adenocarcinoma of the Pancreas

## Interventions

- **PROCEDURE:** 2 passes during EUS-guided fine needle biopsy
- **PROCEDURE:** 3 passes during EUS-guided fine needle biopsy

## Key facts

- **NCT ID:** NCT05043532
- **Lead sponsor:** Orlando Health, Inc.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-18
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-06-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043532, "Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05043532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*